Bob van Gemen
Directeur/Membre du Conseil chez Genome Diagnostics BV
Profil
Bob van Gemen is a Non-Executive Director at Genome Diagnostics BV since 2021.
He was previously the Chief Executive Officer at PrimaGen Holding BV and ViroClinics Biosciences BV from 2011 to 2020.
He also worked as a Principal at Akzo Nobel NV.
Dr. van Gemen holds a doctorate degree from the University of Leiden.
Postes actifs de Bob van Gemen
| Sociétés | Poste | Début |
|---|---|---|
Genome Diagnostics BV
 Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Directeur/Membre du Conseil | 01/08/2021 |
Anciens postes connus de Bob van Gemen
| Sociétés | Poste | Fin |
|---|---|---|
ViroClinics Biosciences BV
 ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | Directeur Général | 01/08/2020 |
| AKZO NOBEL N.V. | Corporate Officer/Principal | - |
PrimaGen Holding BV
 PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Directeur Général | - |
Formation de Bob van Gemen
| University of Leiden | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AKZO NOBEL N.V. | Process Industries |
| Entreprise privées | 3 |
|---|---|
PrimaGen Holding BV
PrimaGen Holding BV Miscellaneous Commercial ServicesCommercial Services PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands. | Commercial Services |
ViroClinics Biosciences BV
ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | Health Technology |
Genome Diagnostics BV
Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Health Technology |
